MA50921A - Sels et formes cristallines d'un modulateur allostérique positif du gabaa - Google Patents
Sels et formes cristallines d'un modulateur allostérique positif du gabaaInfo
- Publication number
- MA50921A MA50921A MA050921A MA50921A MA50921A MA 50921 A MA50921 A MA 50921A MA 050921 A MA050921 A MA 050921A MA 50921 A MA50921 A MA 50921A MA 50921 A MA50921 A MA 50921A
- Authority
- MA
- Morocco
- Prior art keywords
- gabaa
- salts
- crystalline forms
- positive allosteric
- allosteric modulator
- Prior art date
Links
- 229940126027 positive allosteric modulator Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal Substances (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725805P | 2018-08-31 | 2018-08-31 | |
| US16/517,369 US10562930B1 (en) | 2018-08-31 | 2019-07-19 | Salts and crystal forms of GABAA positive allosteric modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50921A true MA50921A (fr) | 2020-09-23 |
Family
ID=69528249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050921A MA50921A (fr) | 2018-08-31 | 2019-08-30 | Sels et formes cristallines d'un modulateur allostérique positif du gabaa |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10562930B1 (fr) |
| EP (1) | EP3710465B1 (fr) |
| JP (2) | JP7199739B2 (fr) |
| KR (1) | KR20210054546A (fr) |
| CN (1) | CN113473991A (fr) |
| AU (1) | AU2019333310A1 (fr) |
| BR (1) | BR112021003727A2 (fr) |
| CA (1) | CA3111193A1 (fr) |
| IL (1) | IL281143A (fr) |
| MA (1) | MA50921A (fr) |
| MX (1) | MX2021002382A (fr) |
| TW (2) | TWI823999B (fr) |
| WO (1) | WO2020047434A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017007902B1 (pt) * | 2014-10-16 | 2023-12-05 | Sage Therapeutics, Inc | Composto e seu sal, composição farmacêutica e uso do referido composto e seu sal na fabricação de um medicamento para o tratamento de distúrbios do sistema nervoso central |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| CN113939298A (zh) * | 2018-12-14 | 2022-01-14 | 普拉西斯精密医药公司 | 用于治疗抑郁症的方法 |
| CN115551514A (zh) | 2020-03-25 | 2022-12-30 | 萨奇治疗股份有限公司 | 用于治疗呼吸系统病症的药物的用途 |
| WO2022006541A1 (fr) * | 2020-07-02 | 2022-01-06 | Praxis Precision Medicines, Inc. | Méthodes pour le traitement d'un trouble de l'adaptation |
| EP4294819A1 (fr) | 2021-02-18 | 2023-12-27 | Praxis Precision Medicines, Inc. | Sels d'hémi-citrate de modulateur allostérique positif de gaba-a et forme cristalline correspondantes |
| WO2022177718A1 (fr) | 2021-02-18 | 2022-08-25 | Sage Therapeutics, Inc. | Utilisation d'un stéroïde neuroactif pour le traitement d'un dysfonctionnement sexuel |
| US20240207366A1 (en) | 2021-04-27 | 2024-06-27 | Kyungpook National University Industry-Academic Cooperation Foundation | Food composition and pharmaceutical composition for preventing or alleviating sarcopenia, containing low-molecular-weight collagen as active ingredient |
| WO2023159035A1 (fr) | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs pour le traitement de troubles liés au snc |
| WO2023164386A1 (fr) * | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs pour le traitement de maladies ou d'états gastro-intestinaux |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69634039T2 (de) | 1995-06-06 | 2005-12-08 | Euro-Celtique S.A. | Steroidderivate der Androstan- und der Pregnanreihe |
| US6780853B1 (en) | 1995-06-06 | 2004-08-24 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
| CA2372342A1 (fr) | 1999-04-29 | 2000-11-09 | Derk J. Hogenkamp | Steroides substitues par heterocycle 3alpha-hydroxy-3beta-methoxymethyl-21- ayant un pouvoir anesthesique |
| WO2005105822A2 (fr) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | Procede de fabrication de steroides 3-alpha-hydroxy sustitues, nouveaux derives de steroides et leurs applications |
| US20060074059A1 (en) | 2004-08-26 | 2006-04-06 | Goliber Philip A | Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one |
| PL2168585T3 (pl) | 2005-06-09 | 2012-05-31 | Euro Celtique Sa | Kompozycje farmaceutyczne steroidów neuroaktywnych i ich zastosowania |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| BR112017007902B1 (pt) * | 2014-10-16 | 2023-12-05 | Sage Therapeutics, Inc | Composto e seu sal, composição farmacêutica e uso do referido composto e seu sal na fabricação de um medicamento para o tratamento de distúrbios do sistema nervoso central |
| AU2018364659A1 (en) | 2017-11-10 | 2020-05-28 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| CN113939298A (zh) | 2018-12-14 | 2022-01-14 | 普拉西斯精密医药公司 | 用于治疗抑郁症的方法 |
-
2019
- 2019-07-19 US US16/517,369 patent/US10562930B1/en active Active
- 2019-08-30 TW TW108131297A patent/TWI823999B/zh active
- 2019-08-30 JP JP2020517339A patent/JP7199739B2/ja active Active
- 2019-08-30 TW TW112141287A patent/TWI850138B/zh active
- 2019-08-30 AU AU2019333310A patent/AU2019333310A1/en active Pending
- 2019-08-30 CN CN201980071246.9A patent/CN113473991A/zh active Pending
- 2019-08-30 BR BR112021003727-6A patent/BR112021003727A2/pt unknown
- 2019-08-30 MX MX2021002382A patent/MX2021002382A/es unknown
- 2019-08-30 CA CA3111193A patent/CA3111193A1/fr active Pending
- 2019-08-30 MA MA050921A patent/MA50921A/fr unknown
- 2019-08-30 EP EP19842855.9A patent/EP3710465B1/fr active Active
- 2019-08-30 WO PCT/US2019/049103 patent/WO2020047434A1/fr active Application Filing
- 2019-08-30 KR KR1020217009437A patent/KR20210054546A/ko not_active Application Discontinuation
- 2019-11-27 US US16/698,057 patent/US10927141B2/en active Active
-
2021
- 2021-01-07 US US17/143,602 patent/US20220024967A1/en not_active Abandoned
- 2021-02-28 IL IL281143A patent/IL281143A/en unknown
-
2022
- 2022-12-14 JP JP2022199092A patent/JP2023036708A/ja active Pending
-
2023
- 2023-12-05 US US18/529,117 patent/US20240140985A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210054546A (ko) | 2021-05-13 |
| TW202024108A (zh) | 2020-07-01 |
| US10927141B2 (en) | 2021-02-23 |
| BR112021003727A2 (pt) | 2021-05-25 |
| EP3710465A1 (fr) | 2020-09-23 |
| TW202408461A (zh) | 2024-03-01 |
| AU2019333310A1 (en) | 2021-04-08 |
| CA3111193A1 (fr) | 2020-03-05 |
| US20200071350A1 (en) | 2020-03-05 |
| US20220024967A1 (en) | 2022-01-27 |
| IL281143A (en) | 2021-04-29 |
| TWI823999B (zh) | 2023-12-01 |
| CN113473991A (zh) | 2021-10-01 |
| US10562930B1 (en) | 2020-02-18 |
| EP3710465A4 (fr) | 2020-09-23 |
| EP3710465B1 (fr) | 2024-08-14 |
| TWI850138B (zh) | 2024-07-21 |
| MX2021002382A (es) | 2021-08-11 |
| WO2020047434A1 (fr) | 2020-03-05 |
| JP7199739B2 (ja) | 2023-01-06 |
| JP2021504297A (ja) | 2021-02-15 |
| JP2023036708A (ja) | 2023-03-14 |
| US20240140985A1 (en) | 2024-05-02 |
| US20200255471A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50921A (fr) | Sels et formes cristallines d'un modulateur allostérique positif du gabaa | |
| MA52493A (fr) | Sels d'un inhibiteur de fgfr | |
| DK3844407T3 (da) | Sæt af plader med en mekanisk låseanordning | |
| MA54458A (fr) | Formes cristallines et formes salines d'un inhibiteur de kinase | |
| MA50223A (fr) | Sels inhibiteurs de ferroportine | |
| MA51066A (fr) | Inhibiteurs d'intégrine | |
| MA47596A (fr) | Formes cristallines du dérivé 4-pyrimidinesulfamide aprocitentan | |
| MA54087A (fr) | Sels cristallins d'un inhibiteur de la kallicréine plasmatique | |
| MA46866A (fr) | Une forme cristalline d'un inhibiteur de magl | |
| MA54638A (fr) | Formes cristallines d'un stimulateur de sgc | |
| ES2720281R1 (es) | Calibracion de un sensor magnetico | |
| MA56001A (fr) | Formes de sel cristallin d'un inhibiteur de kinase | |
| MA55801A (fr) | Formes solides d'un inhibiteur de glyt1 | |
| MA53671A (fr) | Formes cristallines d'un agoniste du récepteur farnésoïde x | |
| DK3725786T3 (da) | KRYSTALLINSK FORM OG SALTFORM AF TGF-ßRI INHIBITOR OG FORBEREDELSESMETODE FOR DETTE | |
| SG11202102110PA (en) | Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor | |
| DK4313945T3 (da) | Krystallinsk hydrobromidsalt af 5-MeO-DMT | |
| FR3086961B1 (fr) | Projection de bfuhp a des fins de renforcement et de regeneration de structures preexistantes | |
| DK3476188T3 (da) | Fremgangsmåde og system til bestemmelse og lagring af overfladeforhold for en mark | |
| MA56445A (fr) | Dérivé de tétrahydroisoquinoléine substitué utilisé comme modulateur allostérique positif de d1 | |
| ES1268871Y (es) | Reloj de teleasistencia | |
| SG11202009262VA (en) | Salts of compounds and crystals thereof | |
| DK3650892T3 (da) | Et system til måling af undervandslyd | |
| ES1297746Y (es) | Cajon de persiana de anclaje rapido | |
| DK3898638T3 (da) | Krystallinske former af en par4-hæmmer |